Evidence map›Paper›PMID 38403723›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2024

Altered biodistribution of [

T van de Weijer, F Bemer, J de Vos-Geelen, B Hermans, C Mitea, J A J van der Pol, T Lodewick, J E Wildberger, F M Mottaghy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Normal organ [European journal of nuclear medicine and molecular imaging · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

T van de WeijerDepartment of Radiology and Nuclear Medicine, ENETS Center of Excellence, Maastricht University Medical Center (MUMC+), P. Debeylaan 25, P.O. Box 5800, 6202, 6229 HX, AZ, Maastricht, The Netherlands.ORCID 0000-0003-3485-7881
F BemerDepartment of Radiology and Nuclear Medicine, ENETS Center of Excellence, Maastricht University Medical Center (MUMC+), P. Debeylaan 25, P.O. Box 5800, 6202, 6229 HX, AZ, Maastricht, The Netherlands.
J de Vos-GeelenDepartment of Medical Oncology, ENETS Center of Excellence, MUMC+, P. Debeylaan 25, P.O. Box 5800, 6202, 6229 HX, AZ, Maastricht, The Netherlands.ORCID 0000-0003-2578-1766
B HermansDepartment of Medical Oncology, ENETS Center of Excellence, MUMC+, P. Debeylaan 25, P.O. Box 5800, 6202, 6229 HX, AZ, Maastricht, The Netherlands.ORCID 0000-0003-4831-3690
C MiteaDepartment of Radiology and Nuclear Medicine, ENETS Center of Excellence, Maastricht University Medical Center (MUMC+), P. Debeylaan 25, P.O. Box 5800, 6202, 6229 HX, AZ, Maastricht, The Netherlands.ORCID 0000-0001-5885-957X
J A J van der PolDepartment of Radiology and Nuclear Medicine, ENETS Center of Excellence, Maastricht University Medical Center (MUMC+), P. Debeylaan 25, P.O. Box 5800, 6202, 6229 HX, AZ, Maastricht, The Netherlands.ORCID 0000-0002-5698-3849
T LodewickDepartment of Radiology and Nuclear Medicine, ENETS Center of Excellence, Maastricht University Medical Center (MUMC+), P. Debeylaan 25, P.O. Box 5800, 6202, 6229 HX, AZ, Maastricht, The Netherlands.ORCID 0000-0001-5388-1575
J E WildbergerDepartment of Radiology and Nuclear Medicine, ENETS Center of Excellence, Maastricht University Medical Center (MUMC+), P. Debeylaan 25, P.O. Box 5800, 6202, 6229 HX, AZ, Maastricht, The Netherlands.ORCID 0000-0002-4810-6854
F M MottaghyDepartment of Radiology and Nuclear Medicine, ENETS Center of Excellence, Maastricht University Medical Center (MUMC+), P. Debeylaan 25, P.O. Box 5800, 6202, 6229 HX, AZ, Maastricht, The Netherlands. fmottaghy@ukaachen.de.ORCID 0000-0002-7212-6521

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe need for an interval between the administration of long-acting Somatostatin Receptor Analogues (SSA) and the [

methodsRetrospectively, 35 patients with NENs were included. [

resultsTreatment with SSA resulted in a significantly higher bloodpool activity and lower visceral tracer uptake. This effect was maintained after a 2nd cycle of SSA therapy. Furthermore, there was an inverse relationship between bloodpool tracer availability and visceral tracer binding and a positive correlation between bloodpool tracer availability and primary tumor tracer uptake. With an interval of up to 5 days, there was a significantly higher bloodpool activity than at longer intervals.

conclusionAbsolute comparison of the SUV on [

Indexed as

Neuroendocrine TumorsOctreotideOrganometallic CompoundsPositron Emission Tomography Computed TomographySomatostatinAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRadiopharmaceuticalsRetrospective StudiesTissue DistributionGa(III)-DOTATOCOctreotideOrganometallic CompoundsRadiopharmaceuticalsSomatostatin68Ga-DOTATOCBiodistributionNENsSomatostatin receptor analogue therapy

Identifiers

PMID38403723
PMCPMC11178651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.